To appraise the clinical and cost effectiveness of tofacitinib within its marketing authorisation for treating moderately to severely active ulcerative colitis.
 
Status In progress
Process STA pre-2018
ID number 1218

Provisional Schedule

Expected publication 31 October 2018

Project Team

Project lead Thomas Feist

Email enquiries

Consultees

Companies sponsors Pfizer Ltd
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Crohn's and Colitis UK
Professional groups British Society of Gastroenterology
  Royal College of Physicians
  UK Clinical Pharmacy Association

Commentators

Comparator companies Abbvie
  Aspen
  Merck Sharp & Dohme
  Takeda UK
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health and Social Services and Public Safety, Northern Ireland
  Healthcare Improvement Scotland
  Welsh Health Specialised Services Committee

Timeline

Key events during the development of the guidance:

Date Update
01 October 2018 - 12 October 2018 Final appraisal determination
16 August 2018 Committee meeting: 1
09 March 2018 Invitation to participate
09 March 2018 In progress, .
20 September 2017 - 18 October 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance